WAVE Life Sciences (NASDAQ:WVE) Insider Chandra Vargeese Sells 3,228 Shares

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chandra Vargeese sold 3,228 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the sale, the insider directly owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This represents a 0.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

WAVE Life Sciences Stock Performance

Shares of WAVE Life Sciences stock traded down $0.32 on Wednesday, hitting $13.27. The company had a trading volume of 2,543,164 shares, compared to its average volume of 3,266,049. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73. The stock has a 50 day moving average of $14.99 and a 200-day moving average of $10.38. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -17.69 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The company had revenue of $7.61 million during the quarter, compared to analysts’ expectations of $9.85 million. Equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on WVE shares. Leerink Partners reiterated an “outperform” rating on shares of WAVE Life Sciences in a report on Monday, December 8th. HC Wainwright upped their target price on WAVE Life Sciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Friday, December 19th. Morgan Stanley set a $28.00 price objective on WAVE Life Sciences in a research report on Monday, December 8th. B. Riley Financial upped their price objective on WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Citigroup raised their target price on WAVE Life Sciences from $16.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Fourteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.69.

Institutional Investors Weigh In On WAVE Life Sciences

Large investors have recently added to or reduced their stakes in the company. Virtus Investment Advisers LLC lifted its holdings in WAVE Life Sciences by 10.2% during the second quarter. Virtus Investment Advisers LLC now owns 13,060 shares of the company’s stock valued at $85,000 after purchasing an additional 1,210 shares during the last quarter. Deutsche Bank AG lifted its position in shares of WAVE Life Sciences by 1.5% during the fourth quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock worth $1,627,000 after acquiring an additional 1,441 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after acquiring an additional 1,802 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of WAVE Life Sciences by 32.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock worth $138,000 after acquiring an additional 1,972 shares during the period. Finally, Velan Capital Investment Management LP grew its position in shares of WAVE Life Sciences by 15.4% in the second quarter. Velan Capital Investment Management LP now owns 15,000 shares of the company’s stock valued at $98,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.